Sight Diagnostics
About Sight Diagnostics
Sight Diagnostics is a healthcare AI company at the forefront of revolutionizing blood diagnostics through advanced machine vision and artificial intelligence. Their flagship product, Sight OLO, is a compact, automated hematology analyzer designed to deliver lab-grade Complete Blood Count (CBC) results, including a five-part differential, in minutes. This is achieved using just two drops of blood, obtainable via a finger prick or venous sample. The technology captures thousands of high-resolution images of the blood sample using digital fluorescent microscopy, which are then analyzed by proprietary machine-learning algorithms to differentiate cell types and identify anomalies.
OLO addresses critical limitations in traditional laboratory testing by enabling rapid, decentralized diagnostics at the point-of-care. This capability is particularly beneficial for clinics, urgent care centers, small hospitals, and resource-limited settings, significantly reducing turnaround times from hours or days to mere minutes. The device has received FDA 510(k) clearance for use in moderate complexity laboratories in the United States and CE Mark approval for point-of-care settings in Europe and other international markets, demonstrating its clinical validation and global applicability.
Beyond its core CBC capabilities, Sight Diagnostics leverages its AI-driven platform to expand disease detection. The company’s foundational work included the Parasight platform for malaria diagnosis, which has been deployed in numerous countries. Ongoing research and development efforts are focused on identifying additional diseases and biomarkers, including those indicative of COVID-19 severity, sepsis, and cancer, aiming to integrate smarter, more accessible blood testing seamlessly into everyday clinical practice and improve patient outcomes through faster, more comprehensive diagnostic insights.
Focus Areas
Business Intelligence
| Key Investors | Koch Disruptive Technologies, Longliv Ventures, OurCrowd, BridgeOne Capital China, CK Hutchison, Dancap Family Investment Office, ForMED Ventures, Innovation Endeavors, Jack Nicklaus II, Steven Esrick, Go Capital, New Alliance Capital, GEOC |
| Partnerships | Sheba Medical Center (Israel), Oxford University Hospital Trust (UK), Superdrug (UK pharmacy chain), Pfizer, American Association for Clinical Chemistry (AACC) |
| Technology | AI, machine vision, digital fluorescent microscopy, computer vision algorithms, proprietary algorithms, single-use test kits, dry instrument, Failsafe self-test system |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Sight Diagnostics' OLO analyzer offers significant advantages by providing lab-grade Complete Blood Count (CBC) results in approximately 10 minutes directly at the point of care. This rapid turnaround time enables faster diagnostic insights and more immediate treatment decisions, which is crucial in urgent care, emergency departments, and outpatient clinics. The device's ability to use just a few drops of blood, often from a finger-prick, enhances patient comfort, particularly for pediatric patients, and streamlines the sample collection process. Its compact size and ease of use make it accessible for various clinical settings, reducing the reliance on centralized labs and improving workflow efficiency. Furthermore, the underlying AI and machine vision technology holds promise for future diagnostic expansions, potentially allowing for the detection of other critical health conditions through software updates.
The OLO device is a self-contained desktop unit that provides results directly on-screen, via printout, or email. Its digital output capabilities suggest potential for integration with Electronic Medical Record (EMR) systems to streamline data management and patient record keeping, facilitating a seamless flow of diagnostic information within clinical workflows.
What the Web Says
Sight Diagnostics is an Israeli medical device company that has developed the OLO analyzer, a compact, AI-powered device for rapid complete blood count (CBC) testing using a finger-prick or venous blood sample. The device aims to provide lab-grade results within minutes at the point of care, making it suitable for clinics and smaller laboratories. While the technology has been praised for its innovation and potential to improve patient outcomes, the company has faced significant challenges, including recent layoffs of all employees and being on the brink of closure.
Overall: MixedStrengths
- Provides rapid, lab-grade complete blood count (CBC) results in minutes.
- Uses a minimal amount of blood, including finger-prick samples.
- Compact, lightweight, and easy to install, making it suitable for point-of-care settings.
- Does not require reagents or manual quality control tests, simplifying use.
- Utilizes AI and computer vision for accurate analysis of blood samples.
- Offers better performance and faster results at a lower price compared to traditional lab machines (company claim).
Limitations
- The company has laid off all employees and is on the brink of closure as of April 2026.
- High staff turnover has been reported, adding stress to the job.
- Some employees have expressed concerns about management and work-life balance.
- Product only runs one category of tests (hematology), requiring other machines for comprehensive patient care.
- Questions raised on Reddit about the company's similarity to Theranos, though Sight Diagnostics' product has FDA approval.
- One review from Oxford University Hospitals NHS Foundation Trust denied Sight Diagnostics' claim of better performance, less blood, faster results, and lower price compared to Sysmex XN-Series.
Based on reviews from: Indeed.com, Reddit, Forbes, NoCamels, Fierce Biotech, eBay, Silicon Canals, PMC, G2, Capterra
Last updated: 2026-07-19
Videos
News, demos, and interviews about Sight Diagnostics.
Videos load interactively. If none appear, search YouTube for Sight Diagnostics →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Sight Diagnostics.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]